Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
Status:
Terminated
Trial end date:
2019-07-03
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well olaparib works in treating participants with prostate
cancer that has not spread to other parts of the body (localized). Olaparib may stop the
growth of tumor cells by interfering with the activity of a substance called PARP, which is
inside cells. Giving olaparib before surgery may make the tumor smaller and reduce the amount
of normal tissue that needs to be removed.